Moderna, Inc. (MRNA) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$143.77

Open

$145.41

Day range

$142.30 – $148.93

Volume

8.8M

About Moderna, Inc.

Latest MRNA news

• Steady stream of crossover rounds stock biotech’s IPO pipeline
  IPO & M&A · Sep 9, 2026

  The biotechnology sector is experiencing a resurgence in initial public offerings (IPOs), driven by a steady influx of crossover funding rounds that have bolstered investor confidence. In recent months, public investors have shown renewed interest in biotech firms, paving the way for a series of anticipated public debuts. This renewed enthusiasm is reflected in the increasing number of companies successfully securing crossover investments, which typically involve both private and public investors, thereby enhancing their market readiness. The implications for the market are significant, as a robust IPO pipeline can attract further investment into the biotech sector, potentially leading to a more favorable environment for innovation and development. As companies prepare for their public offerings, the influx of capital from crossover rounds not only strengthens their financial positions but also signals to other investors that there is a viable path to profitability in the sector. This trend may encourage additional firms to pursue IPOs, further stimulating market activity and possibly leading to a competitive landscape that benefits both investors and consumers through accelerated advancements in biotechnology.

• There are some tremendous healthcare companies in bull market mode, says Jim Cramer
  Market Outlook · Sep 8, 2026

  Jim Cramer, the host of CNBC's "Mad Money," has highlighted a selection of healthcare companies that are currently thriving in what he describes as a bull market. Cramer emphasized that while artificial intelligence continues to capture headlines, investors should not overlook the robust performance and potential of healthcare stocks. He pointed to several firms that are not only showing strong earnings but also exhibiting resilience amid broader market fluctuations. Cramer’s analysis suggests that the healthcare sector is well-positioned for growth, driven by factors such as an aging population, increasing demand for innovative treatments, and advancements in biotechnology. This positive outlook could lead to increased investment in these companies, potentially boosting stock prices and attracting institutional interest. As investors seek to diversify their portfolios beyond tech-driven stocks, Cramer’s insights may encourage a shift towards healthcare, which could further enhance the sector's momentum in the coming months.

• Enhanced FDA-SEC Collaboration: How Life Sciences Companies Think About Disclosure, Insider Trading, and Prediction Markets
  Financial Regulation · Sep 8, 2026

  On August 31, 2026, the U.S. Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) announced a new Memorandum of Understanding (MOU) aimed at enhancing collaboration between the two agencies. This initiative is expected to significantly impact how life sciences companies approach disclosure practices, insider trading, and prediction markets. By fostering a more integrated regulatory environment, the agencies aim to improve the transparency and accuracy of information provided to investors regarding drug approvals and clinical trial results. The MOU signals a proactive stance by regulators to address the complexities of the life sciences sector, where timely and accurate disclosures are critical for investor decision-making. As the FDA continues to evaluate new therapies and treatments, the SEC's involvement will likely lead to stricter scrutiny of disclosures related to clinical outcomes and potential market-moving events. This heightened oversight could deter insider trading and promote fairer market practices, as companies will need to ensure compliance with both agencies' standards. Market implications are substantial, as enhanced regulatory scrutiny may lead to increased volatility in life sciences stocks, particularly around key FDA announcements. Companies will need to adopt more rigorous disclosure protocols to mitigate risks associated with non-compliance. Investors should prepare for a landscape where information asymmetry is reduced, potentially leading to more informed trading strategies and a shift in how market participants assess the value of biotech and pharmaceutical firms.

• AI will help find cure for cancer ‘within our lifetimes’, says Arm Holdings chief
  Guardian Business · Sep 8, 2026

  Arm Holdings CEO Rene Haas has expressed optimism that advancements in artificial intelligence (AI) could lead to significant breakthroughs in cancer treatment within the next few decades. Speaking at a recent industry conference, Haas highlighted the potential of AI to analyze vast datasets, identify patterns, and accelerate drug discovery processes, which could ultimately result in more effective therapies for various cancer types. This assertion comes at a time when the intersection of technology and healthcare is garnering increased attention from investors and researchers alike. The integration of AI in medical research not only promises to enhance the efficiency of clinical trials but also to personalize treatment options for patients. As companies like Arm, which specializes in semiconductor technology, continue to innovate, the implications for the biotech sector are profound. Investors may see opportunities in firms that leverage AI to develop new treatments, potentially reshaping the landscape of cancer care. Market analysts are closely watching developments in this area, as the successful application of AI in oncology could lead to significant financial returns for tech and pharmaceutical companies alike. As the healthcare industry increasingly embraces digital transformation, the collaboration between AI firms and biotech companies may pave the way for groundbreaking advancements, making the prospect of curing cancer more attainable than ever before.

• Tech stocks lead a rally on Wall Street as bond yields ease some more
  Bond Market · Sep 3, 2026

  U.S. stock markets experienced a notable rally on Wednesday, driven primarily by gains in major technology stocks as bond yields continued to ease. The decline in government bond yields has contributed to a more favorable risk appetite among investors, allowing tech shares to regain momentum after a period of volatility. This shift comes amid a backdrop of fluctuating oil prices, with Brent crude stabilizing near $95 a barrel, further supporting market sentiment. The resurgence in tech stocks, particularly highlighted by a significant rally in shares of vaccine manufacturer Moderna, has helped lift the main U.S. stock indexes modestly higher. This positive movement contrasts with recent market trends, where rising bond yields and geopolitical uncertainties had pressured stock prices, particularly in the semiconductor sector. Analysts suggest that the easing of yields may provide a more conducive environment for growth-oriented sectors, potentially leading to a broader market recovery if the trend continues. However, the overall economic landscape remains complex, with recent U.S. jobs data offering little clarity on the health of the economy or the prospects for interest rate adjustments. Investors are likely to remain cautious, monitoring both economic indicators and geopolitical developments, particularly in the Middle East, which could influence market dynamics and investor sentiment in the coming weeks.

• SEC, FDA sign info-sharing agreement as a ‘signal to the market’ on insider trading
  Financial Regulation · Sep 2, 2026

  The Securities and Exchange Commission (SEC) and the Food and Drug Administration (FDA) have formalized a three-year information-sharing agreement aimed at enhancing regulatory oversight and enforcement against insider trading, particularly in the pharmaceutical sector. This collaboration is expected to bolster the SEC's ability to detect and address potential insider trading activities that may arise from non-public information related to drug approvals and other FDA actions. Market analysts view this agreement as a significant signal to investors and companies within the pharmaceutical industry, indicating that regulatory scrutiny will intensify. By facilitating the exchange of critical information between the two agencies, the SEC and FDA aim to create a more transparent environment, potentially deterring illicit trading practices that can undermine market integrity. As a result, pharmaceutical stocks may experience increased volatility as investors reassess the risks associated with insider trading and regulatory compliance. The implications of this agreement extend beyond mere enforcement; it also highlights a growing recognition of the interconnectedness between regulatory bodies in safeguarding market integrity. As the SEC and FDA enhance their collaboration, companies in the biotech and pharmaceutical sectors may need to implement more robust compliance measures to navigate the heightened scrutiny, which could lead to increased operational costs. Overall, this partnership underscores the commitment of both agencies to uphold fair market practices and protect investors from the risks associated with insider trading.

• Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
  Yahoo Finance · Sep 2, 2026

  Recent analysis has highlighted two under-$20 healthcare stocks favored by billionaire investors, signaling potential opportunities in a sector that has regained investor interest. With the recent resurgence of companies like Moderna, which has seen a significant uptick in its stock price, the healthcare and biotech sectors are drawing attention as viable alternatives to the tech-heavy AI investments that have dominated the market narrative. The two stocks identified are positioned in a market that is increasingly focused on innovation and long-term growth potential. Investors are advised to consider the fundamentals of these companies, including their pipeline developments and market strategies, rather than simply following billionaire portfolios without due diligence. The healthcare sector, particularly in biotech, can offer substantial returns, but it also carries inherent risks associated with regulatory approvals and market competition. As the market continues to evolve, these under-$20 stocks may provide an entry point for investors looking to diversify their portfolios. However, it is crucial to remain cautious and conduct thorough research, as the volatility in the healthcare sector can lead to significant price fluctuations. Overall, the renewed focus on healthcare investments could reshape market dynamics, especially if these companies deliver on their growth promises.

• Dow Jones Futures Rise As Oil Prices Fall; Dell, Credo, Palo Alto Are Earnings Movers
  Yahoo Finance · Sep 2, 2026

  Dow Jones futures experienced a modest rise early Wednesday as oil prices declined, providing a potential boost to investor sentiment. This shift comes after a turbulent period where major U.S. stock indexes, including the Dow and Nasdaq 100, fell below their 50-day moving averages amid escalating oil prices driven by geopolitical tensions. The recent military exchanges between the U.S. and Iran have heightened concerns over supply disruptions, contributing to market volatility. In the earnings arena, companies like Dell, Credo, and Palo Alto Networks are drawing attention as their financial results could influence market direction. Despite beating earnings expectations, Target's stock saw a decline, indicating that investor sentiment may be more sensitive to broader market conditions rather than individual company performance. Conversely, Moderna's significant rise following news of a promising cancer vaccine underscores the potential for biotech stocks to thrive amid market uncertainty. As oil prices retreat, investors may reassess their positions, particularly in energy and technology sectors, which have been under pressure. The interplay between oil prices, geopolitical developments, and corporate earnings will likely continue to shape market dynamics in the coming days.

• ‘All it will take is one screw-up’: AI groups race to limit bioweapon risks
  FT Companies · Sep 2, 2026

  As artificial intelligence continues to advance, executives and biosecurity experts are increasingly alarmed about the potential for these technologies to be misused in the creation of bioweapons. The rapid development of AI tools capable of generating biological data raises significant concerns about the ease with which individuals could design novel viruses or other harmful pathogens. This has prompted a race among AI groups to implement safeguards and limit the risks associated with these powerful technologies. The implications for markets are profound, particularly in sectors related to biotechnology and pharmaceuticals. Investors are likely to scrutinize companies involved in AI and genetic engineering more closely, assessing their risk management strategies and ethical frameworks. Regulatory bodies may also step up oversight, potentially leading to increased compliance costs and affecting innovation timelines. As the threat of bioweapons looms, the urgency for robust biosecurity measures could reshape investment priorities, with a greater emphasis on companies that prioritize safety and ethical considerations in their AI applications. The situation underscores a critical intersection of technology and public safety, where the stakes are high and the margin for error is slim. Industry leaders are advocating for collaborative efforts to establish guidelines and best practices that can mitigate the risks while still fostering innovation. As these discussions unfold, the market will be watching closely to see how companies navigate this complex landscape and what measures they implement to prevent a potential catastrophe.

• US Market Outlook: Wait-and-see mood ahead of Waller's speech; Google shares dip despite strong earnings amid concerns over slow AI monetization; Moderna expands convertible bond issuance to $2.6 billion; Marvel slides as earnings guidance misses ex
  Market Outlook · Aug 28, 2026

  U.S. markets are adopting a cautious stance ahead of Federal Reserve Governor Christopher Waller's upcoming speech, which is anticipated to provide insights into the central bank's monetary policy trajectory. Investors are closely monitoring Waller's comments for any hints regarding interest rate adjustments, particularly in light of persistent inflationary pressures and mixed economic indicators. This wait-and-see approach has led to subdued trading volumes as market participants position themselves for potential volatility. In corporate news, Google parent Alphabet reported strong earnings that exceeded analysts' expectations, yet its shares dipped in after-hours trading. The decline is attributed to concerns over the pace of monetization in its artificial intelligence initiatives, which investors fear may not translate into immediate revenue growth. This sentiment reflects a broader apprehension in the tech sector regarding the commercialization of AI technologies, potentially impacting future valuations. Meanwhile, Moderna has announced an expansion of its convertible bond issuance to $2.6 billion, a move aimed at bolstering its financial position as it navigates the post-pandemic landscape and seeks to diversify its product pipeline. This strategic financing could provide the company with the necessary capital to invest in research and development, although it may also dilute existing shareholders' stakes. Lastly, Marvel's stock has taken a hit following a disappointing earnings guidance, raising concerns about its ability to maintain growth in a competitive entertainment landscape. The combination of these factors reflects a complex market environment where investor sentiment is increasingly influenced by both macroeconomic signals and individual company performance.

All 28 articles in the app →

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen